There seems to be a tendency for better survival of ILC compared to NST for patients at low risk of recurrence (luminal breast cancer, smaller tumor size, no or limited nodal involvement), while patients with ILC tend to have worse survival than patients with NST when they are at intermediate-to-high risk of recurrence, as assessed by negative hormone receptor status, large tumor size or many involved lymph nodes. The gene discussed is NR4A1; the disease is breast carcinoma.